関連レポート

液体生検(リキッドバイオプシー)市場：バイオマーカー別、用途別2029年予測

出版元：MarketsandMarkets  出版元について

発行年：2024年6月

定価：Single User License $4950 Multi User License $6650 Corporate User License $8150

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 251ページになります。

商品コード：MAM3655

当レポートの更新版の制作依頼、部分購入やご希望情報の追加等、ご相談可能です。

レポート紹介

エクソソーム診断および治療の世界市場規模は2024年で5900万ドル、2029年に23億4700ドル、市場の平均年成長率は108.9%にて増加すると見込まれています。

レポートはエクソソーム診断および治療の世界市場について2032年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（タイプ別市場、製品サービス別市場、等）を中心に構成されています。また競合状況、主要企業情報（10社）、サプライチェーン分析、バリューチェーン分析なども加味し、エクソソーム診断および治療市場の動向および今後成長性を詳細にレポートしています。

【レポート構成概要】
◆エクソソーム診断および治療市場の世界市場予測2022-2032年
・市場規模(US$)

◆タイプ別、市場-2032年
・エクソソーム診断
・エクソソーム治療
※(市場規模US$)　

◆製品サービス別、市場-2032年
・キット、試薬
・機器、サービス
※(市場規模US$)　

◆ソース別、市場-2032年
・幹細胞
・血液、血漿
・尿
・その他サンプル
※(市場規模US$)　

◆用途別、市場-2032年
・がん
・皮膚疾患
・筋骨格系疾患
・心血管疾患
・その他領域
※(市場規模US$)　

◆エンドユーザー別、市場-2032年
・病院
・診療所、医療現場
※(市場規模US$)　

◆主要国地域別市場-2032年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・韓国、オーストラリア
・その他アジア太平洋
その他地域
※地域、国別に、タイプ別、ソース別、用途別、エンドユーザー別の細分化データ掲載、詳細は目次参照

◆市場分析
・市場ダイナミクス
・サプライチェーン分析
・バリューチェーン分析
・特許分析
・規制状況
・ファイブフォース分析
・主要なステークホルダーと購買基準
・投資と資金調達のシナリオ
・パイプライン分析
・平均価格分析
・エコシステム分析
・主要な会議とイベント
・技術分析
・競合状況
・市場シェア分析

◆エクソソーム診断および治療市場の主要企業プロフィール動向
・BIO-TECHNE
・NANOFCM INC
・SYSTEM BIOSCIENCES, LLC
・CAPITAL BIOSCIENCES, INC
・AMSBIO
・INOVIQ
・DIRECT BIOLOGICS LLC
・REGENEUS LTD
・CUREXSYS
・AEGLE THERAPEUTICS

その他企業
・MERCY BIOANALYTICS
・NANOSOMIX, INC
・EXONOX BIOSCIENCES, INC
・MULTIMMUNE GMBH
・CAPRICOR THERAPEUTICS, INC
・EVOX THERAPEUTICS
・ILIAS BIOLOGICS INC
・RION
・EXOGENUS THERAPEUTICS
・EVERZOM
・KIMERA LABS
（全251頁）

Table of Contents (英文詳細目次）

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS & EXCLUSIONS 28
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
・ FIGURE 1 MARKET SEGMENTATION 28
1.3.2 REGIONS COVERED 29
・ FIGURE 2 REGIONAL SEGMENTATION 29
1.3.3 YEARS CONSIDERED 29
1.3.4 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 30
1.5 RECESSION IMPACT 30

2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
・ FIGURE 3 RESEARCH DESIGN 31
2.1.1 SECONDARY DATA 32
2.1.2 PRIMARY DATA 32
・ FIGURE 4 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES 33
2.2 MARKET ESTIMATION METHODOLOGY 33
・ FIGURE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 33
・ FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 34
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 35
・ FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 35
2.3 MARKET GROWTH RATE PROJECTIONS 37
・ FIGURE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS 37
・ FIGURE 9 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 38
2.4 DATA TRIANGULATION AND MARKET BREAKDOWN 39
・ FIGURE 10 DATA TRIANGULATION METHODOLOGY 39
2.5 RESEARCH ASSUMPTIONS 40
2.6 RISK ASSESSMENT ANALYSIS 40
・ TABLE 1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: RISK IMPACT ANALYSIS 40
2.7 RECESSION IMPACT ANALYSIS 40
・ TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 40
・ TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 41
・ TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 41

3 EXECUTIVE SUMMARY 42
・ FIGURE 11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION) 42
・ FIGURE 12 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY PRODUCT & SERVICE, 2029 VS. 2032 (USD MILLION) 43
・ FIGURE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2029 VS. 2032 (USD MILLION) 43
・ FIGURE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY APPLICATION, 2029 VS. 2032 (USD MILLION) 44
・ FIGURE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2029 VS. 2032 (USD MILLION) 45
・ FIGURE 16 GEOGRAPHICAL SNAPSHOT OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET 46

4 PREMIUM INSIGHTS 47
4.1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET OVERVIEW 47
・ FIGURE 17 EMERGING POTENTIAL OF EXOSOME-BASED LIQUID BIOPSY TO DRIVE MARKET 47
4.2 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE AND COUNTRY (2029) 48
・ FIGURE 18 EXOSOME THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2029 48
4.3 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION) 48
・ FIGURE 19 EXOSOME DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 48

5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
・ FIGURE 20 EXOSOME DIAGNOSTICS AND THERAPEUTIC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49
・ TABLE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS 50
5.2.1 DRIVERS 50
5.2.1.1 EMERGING POTENTIAL OF EXOSOME-BASED LIQUID BIOPSY 50
5.2.1.2 INCREASING INITIATIVES FOR PRODUCT COMMERCIALIZATION 51
5.2.1.3 GROWING OUTSOURCING OF EXOSOME-BASED MANUFACTURING ACTIVITIES 52
5.2.2 RESTRAINTS 52
5.2.2.1 TECHNICAL COMPLEXITIES ASSOCIATED WITH EXOSOME ISOLATION 52
5.2.2.2 STRINGENT REGULATORY REQUIREMENTS 53

5.2.3 OPPORTUNITIES 53
5.2.3.1 GROWING ADOPTION OF EXOSOME BIOMARKERS FOR PERSONALIZED MEDICINE 53
5.2.4 CHALLENGES 54
5.2.4.1 INADEQUATE PROTOCOLS FOR EXOSOME DEVELOPMENT & PRODUCTION 54
5.3 SUPPLY CHAIN ANALYSIS 54
・ FIGURE 21 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS 55
5.4 VALUE CHAIN ANALYSIS 56
・ FIGURE 22 VALUE CHAIN ANALYSIS: MANUFACTURING PROCESSES AND REGULATORY INVESTMENTS ADD MAXIMUM VALUE 56
5.5 PATENT ANALYSIS 57
5.5.1 PATENT ANALYSIS: EXOSOME DIAGNOSTICS 57
・ FIGURE 23 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, JANUARY 2013–OCTOBER 2023 58
・ FIGURE 24 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, BY JURISDICTION 58
5.5.2 PATENT ANALYSIS: EXOSOME THERAPEUTICS 59
・ FIGURE 25 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, JANUARY 2013–OCTOBER 2023 59
・ FIGURE 26 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, BY JURISDICTION 60
5.6 REGULATORY LANDSCAPE 60
5.6.1 REGULATORY SCENARIO 60
5.6.1.1 NORTH AMERICA 61
5.6.1.1.1 US 61
5.6.1.1.2 CANADA 61
5.6.1.2 EUROPE 62
5.6.1.2.1 GERMANY 62
5.6.1.2.2 SPAIN 62
5.6.1.3 ASIA PACIFIC 63
5.6.1.3.1 CHINA 63
5.6.1.3.2 JAPAN 63
5.6.1.3.3 SOUTH KOREA 64
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
・ TABLE 6 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
5.7 PORTER’S FIVE FORCES ANALYSIS 67
・ TABLE 7 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 67
5.7.1 THREAT OF NEW ENTRANTS 67
5.7.2 THREAT OF SUBSTITUTES 67
5.7.3 BARGAINING POWER OF SUPPLIERS 68
5.7.4 BARGAINING POWER OF BUYERS 68
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 68
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 68
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 68
・ FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EXOSOME DIAGNOSTICS & THERAPEUTICS 68
5.8.2 BUYING CRITERIA FOR END USERS 70
・ FIGURE 28 KEY BUYING CRITERIA FOR END USERS 70
5.9 INVESTMENT AND FUNDING SCENARIO 71
・ TABLE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: INVESTMENT & FUNDING SCENARIO 71
5.10 EXOSOME THERAPEUTICS: DEVELOPMENT & MANUFACTURING PROCESS 74
5.10.1 EXOSOME ISOLATION 74
・ TABLE 9 EXOSOME ISOLATION TECHNIQUES 75
5.10.2 EXOSOME CHARACTERIZATION AND QC 76
5.10.3 EXOSOME PRODUCTION 76
5.11 PIPELINE ANALYSIS 76
・ FIGURE 29 EXOSOME PIPELINE, BY INTERVENTION TYPE 77
・ FIGURE 30 EXOSOME PIPELINE, BY PHASE 77
5.11.1 PIPELINE ANALYSIS: EXOSOME THERAPEUTICS 77
・ FIGURE 31 EXOSOME THERAPEUTICS PIPELINE, BY PHASE 78
・ FIGURE 32 EXOSOME THERAPEUTICS PIPELINE, BY REGION 78
5.11.2 PIPELINE ANALYSIS: EXOSOME DIAGNOSTICS 78
・ FIGURE 33 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY APPLICATION 79
・ FIGURE 34 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY COUNTRY 79
・ TABLE 10 PIPELINE PRODUCTS FOR EXOSOME DIAGNOSTICS 80
・ TABLE 11 PIPELINE PRODUCTS FOR EXOSOME THERAPEUTICS 81
5.12 PRICING ANALYSIS 83
5.12.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 83
・ TABLE 12 AVERAGE SELLING PRICE OF EXOSOME DIAGNOSTIC PRODUCTS, BY KEY PLAYER 83
5.12.2 AVERAGE SELLING PRICE TREND, BY REGION 83
5.13 ECOSYSTEM ANALYSIS 84
・ FIGURE 35 EXOSOME DIAGNOSTICS AND THERAPEUTICS: ECOSYSTEM MAP 84
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 85
・ FIGURE 36 REVENUE SHIFT AND NEW POCKETS 85
5.15 KEY CONFERENCES & EVENTS 86
・ TABLE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2024–2025) 86
5.16 TECHNOLOGY ANALYSIS 87
5.16.1 KEY TECHNOLOGIES 87
・ TABLE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: KEY TECHNOLOGIES 87
5.16.2 COMPLIMENTARY TECHNOLOGIES 88
5.16.3 ADJACENT TECHNOLOGIES 89

6 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE 90
6.1 INTRODUCTION 91
・ TABLE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 91
・ TABLE 16 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 91
6.2 EXOSOME DIAGNOSTICS 91
6.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION & DIAGNOSIS TO PROPEL MARKET 91
・ TABLE 17 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 92
・ TABLE 18 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2030–2032 (USD MILLION) 92
・ TABLE 19 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 92
・ TABLE 20 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 93
・ TABLE 21 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 93
・ TABLE 22 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 93
・ TABLE 23 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 94
・ TABLE 24 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 94
6.3 EXOSOME THERAPEUTICS 94
6.3.1 INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH 94
・ TABLE 25 EXOSOME THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 95
・ TABLE 26 EXOSOME THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION) 95
・ TABLE 27 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 95
・ TABLE 28 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 96
・ TABLE 29 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 96
・ TABLE 30 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 96
・ TABLE 31 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 97
・ TABLE 32 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 97

7 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 98
7.1 INTRODUCTION 99
・ TABLE 33 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 99
・ TABLE 34 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2030–2032 (USD MILLION) 99
7.2 KITS & REAGENTS 99
7.2.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTIC KITS TO DRIVE MARKET 99
・ TABLE 35 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2022–2029 (USD MILLION) 100
・ TABLE 36 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2030–2032 (USD MILLION) 100
・ TABLE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 100
・ TABLE 38 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION) 101
・ TABLE 39 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 101
・ TABLE 40 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION) 101
・ TABLE 41 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION) 102
・ TABLE 42 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION) 102
7.3 INSTRUMENTS & SERVICES 103
7.3.1 RISING FOCUS ON OUTSOURCING EXOSOME PREPARATION ACTIVITIES TO SUPPORT MARKET GROWTH 103
・ TABLE 43 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2022–2029 (USD MILLION) 103
・ TABLE 44 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2030–2032 (USD MILLION) 103

8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE 104
8.1 INTRODUCTION 105
・ TABLE 45 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 105
・ TABLE 46 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 105
8.2 STEM CELLS 106
8.2.1 GROWING UPTAKE OF MSC-DERIVED EXOSOMES IN CELLULAR PROCESSES TO DRIVE MARKET 106
・ TABLE 47 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2022–2029 (USD MILLION) 106
・ TABLE 48 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2030–2032 (USD MILLION) 106
・ TABLE 49 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 107
・ TABLE 50 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION) 107
・ TABLE 51 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 107
・ TABLE 52 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION) 108
・ TABLE 53 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION) 108
・ TABLE 54 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION) 108
8.3 BLOOD & BLOOD PLASMA 109
8.3.1 ABILITY TO ENHANCE TREATMENT RESPONSE AND DISEASE DIAGNOSIS TO BOOST DEMAND 109
・ TABLE 55 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2022–2029 (USD MILLION) 109
・ TABLE 56 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2030–2032 (USD MILLION) 109
・ TABLE 57 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION) 110
・ TABLE 58 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION) 110
・ TABLE 59 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION) 110
・ TABLE 60 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION) 111
・ TABLE 61 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION) 111
・ TABLE 62 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION) 111
8.4 URINE 112
8.4.1 RAPID COMMERCIALIZATION OF URINE SAMPLE-BASED DIAGNOSTIC TESTS TO DRIVE MARKET 112
・ TABLE 63 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2022–2029 (USD MILLION) 112
・ TABLE 64 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2030–2032 (USD MILLION) 112
・ TABLE 65 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION) 113
・ TABLE 66 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION) 113
・ TABLE 67 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION) 113
・ TABLE 68 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION) 114
・ TABLE 69 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION) 114
・ TABLE 70 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION) 114
8.5 OTHER SAMPLES 115
・ TABLE 71 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022–2029 (USD MILLION) 115
・ TABLE 72 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2030–2032 (USD MILLION) 115
・ TABLE 73 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 116
・ TABLE 74 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION) 116
・ TABLE 75 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 116
・ TABLE 76 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION) 117
・ TABLE 77 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 117
・ TABLE 78 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION) 117

9 EXOSOME THERAPEUTICS MARKET, BY APPLICATION 118
9.1 INTRODUCTION 119
・ TABLE 79 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 119
・ TABLE 80 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 119
9.2 CANCER 120
9.2.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET 120
・ TABLE 81 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION) 120
・ TABLE 82 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2030–2032 (USD MILLION) 121
・ TABLE 83 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 121
・ TABLE 84 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION) 121
・ TABLE 85 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 122
・ TABLE 86 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION) 122
・ TABLE 87 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 123
・ TABLE 88 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION) 123
9.3 DERMATOLOGICAL DISEASES 124
9.3.1 INCREASING R&D ACTIVITIES FOR WOUND HEALING AND REGENERATIVE MEDICINE TO DRIVE MARKET 124
・ TABLE 89 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION) 124
・ TABLE 90 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2030–2032 (USD MILLION) 125
・ TABLE 91 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 125
・ TABLE 92 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 125
・ TABLE 93 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 126
・ TABLE 94 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 126
・ TABLE 95 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 127
・ TABLE 96 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 127
9.4 MUSCULOSKELETAL DISORDERS 127
9.4.1 RISING INCIDENCE OF OSTEOARTHRITIS TO SUPPORT MARKET GROWTH 127
・ TABLE 97 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2022–2029 (USD MILLION) 128
・ TABLE 98 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2030–2032 (USD MILLION) 129
・ TABLE 99 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 129
・ TABLE 100 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION) 129
・ TABLE 101 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 130
・ TABLE 102 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION) 130
・ TABLE 103 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 131
・ TABLE 104 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION) 131
9.5 CARDIOVASCULAR DISEASES 132
9.5.1 GROWING FOCUS ON TARGETED THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH 132
・ TABLE 105 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION) 132
・ TABLE 106 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2030–2032 (USD MILLION) 132
・ TABLE 107 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 133
・ TABLE 108 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 133
・ TABLE 109 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 133
・ TABLE 110 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 134
・ TABLE 111 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 134
・ TABLE 112 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION) 134
9.6 OTHER APPLICATIONS 135
・ TABLE 113 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 135
・ TABLE 114 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2030–2032 (USD MILLION) 135
・ TABLE 115 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 136
・ TABLE 116 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION) 136
・ TABLE 117 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 136
・ TABLE 118 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION) 137
・ TABLE 119 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 137
・ TABLE 120 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION) 137

10 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER 138
10.1 INTRODUCTION 139
・ TABLE 121 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 139
・ TABLE 122 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 139
10.2 HOSPITALS 139
10.2.1 GROWING COLLABORATIONS WITH PHARMA & BIOPHARMA COMPANIES TO DRIVE MARKET 139
・ TABLE 123 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 140
・ TABLE 124 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2030–2032 (USD MILLION) 140
・ TABLE 125 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 141
・ TABLE 126 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION) 141
・ TABLE 127 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 141
・ TABLE 128 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION) 142
・ TABLE 129 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 142
・ TABLE 130 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION) 142
10.3 CLINICS AND PHYSICIAN SETTINGS 143
10.3.1 RISING ADOPTION OF LIQUID BIOPSY KITS TO SUPPORT MARKET GROWTH 143
・ TABLE 131 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2022–2029 (USD MILLION) 143
・ TABLE 132 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2030–2032 (USD MILLION) 143
・ TABLE 133 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 144
・ TABLE 134 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION) 144
・ TABLE 135 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 144
・ TABLE 136 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION) 145
・ TABLE 137 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION) 145
・ TABLE 138 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION) 145

11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION 146
11.1 INTRODUCTION 147
・ TABLE 139 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 147
・ TABLE 140 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION) 147
11.2 NORTH AMERICA 147
11.2.1 NORTH AMERICA: RECESSION IMPACT 148
・ FIGURE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT 148
・ TABLE 141 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
・ TABLE 142 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 149
・ TABLE 143 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 149
・ TABLE 144 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 150
・ TABLE 145 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 150
・ TABLE 146 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 150
・ TABLE 147 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 151
・ TABLE 148 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 151
・ TABLE 149 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 151
・ TABLE 150 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 152
11.2.2 US 152
11.2.2.1 RISING R&D INITIATIVES FOR DEVELOPMENT OF EXOSOMES TO DRIVE MARKET 152
・ TABLE 151 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 153
・ TABLE 152 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 153
・ TABLE 153 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 153
・ TABLE 154 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 154
・ TABLE 155 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 154
・ TABLE 156 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 154
・ TABLE 157 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 155
・ TABLE 158 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 155
11.2.3 CANADA 155
11.2.3.1 INCREASING FUNDING INITIATIVES FOR GENOMIC-BASED TREATMENTS TO SUPPORT MARKET GROWTH 155
・ TABLE 159 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 156
・ TABLE 160 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 156
・ TABLE 161 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 156
・ TABLE 162 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 157
・ TABLE 163 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 157
・ TABLE 164 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 157
・ TABLE 165 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 158
・ TABLE 166 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 158
11.3 EUROPE 158
11.3.1 EUROPE: RECESSION IMPACT 158
・ FIGURE 38 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT 159
・ TABLE 167 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
・ TABLE 168 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 160
・ TABLE 169 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 160
・ TABLE 170 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 161
・ TABLE 171 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 161
・ TABLE 172 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 161
・ TABLE 173 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 162
・ TABLE 174 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 162
・ TABLE 175 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 162
・ TABLE 176 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 163
11.3.2 GERMANY 163
11.3.2.1 COMMERCIALIZATION OF PIPELINE CANDIDATES TO PROPEL MARKET 163
・ TABLE 177 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 163
・ TABLE 178 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 163
・ TABLE 179 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 164
・ TABLE 180 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 164
・ TABLE 181 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 164
・ TABLE 182 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 165
・ TABLE 183 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 165
・ TABLE 184 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 165
11.3.3 UK 166
11.3.3.1 RISING GROWTH IN LIFE SCIENCES RESEARCH TO DRIVE MARKET 166
・ TABLE 185 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 166
・ TABLE 186 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 166
・ TABLE 187 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 167
・ TABLE 188 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 167
・ TABLE 189 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 167
・ TABLE 190 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 168
・ TABLE 191 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 168
・ TABLE 192 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 168
11.3.4 FRANCE 169
11.3.4.1 PRESENCE OF EMERGING PLAYERS FOR EXOSOME PREPARATION TO FUEL MARKET 169
・ TABLE 193 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
・ TABLE 194 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 169
・ TABLE 195 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 169
・ TABLE 196 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 170
・ TABLE 197 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 170
・ TABLE 198 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 170
・ TABLE 199 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 171
・ TABLE 200 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 171
11.3.5 ITALY 171
11.3.5.1 RISING GROWTH IN BIOTECH SECTOR TO BOOST DEMAND 171
・ TABLE 201 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 172
・ TABLE 202 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 172
・ TABLE 203 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 172
・ TABLE 204 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 173
・ TABLE 205 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 173
・ TABLE 206 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 173
・ TABLE 207 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 174
・ TABLE 208 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 174
11.3.6 SPAIN 174
11.3.6.1 INCREASING INITIATIVES FOR EXOSOME RESEARCH TO SUPPORT MARKET GROWTH 174
・ TABLE 209 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
・ TABLE 210 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 175
・ TABLE 211 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 175
・ TABLE 212 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 175
・ TABLE 213 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 176
・ TABLE 214 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 176
・ TABLE 215 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 176
・ TABLE 216 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 177
11.3.7 REST OF EUROPE 177
・ TABLE 217 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 177
・ TABLE 218 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 177
・ TABLE 219 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 178
・ TABLE 220 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 178
・ TABLE 221 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 178
・ TABLE 222 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 179
・ TABLE 223 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 179
・ TABLE 224 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 179
11.4 ASIA PACIFIC 180
11.4.1 ASIA PACIFIC: RECESSION IMPACT 180
・ TABLE 225 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 180
・ TABLE 226 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION) 181
・ TABLE 227 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 181
・ TABLE 228 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 181
・ TABLE 229 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 182
・ TABLE 230 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 182
・ TABLE 231 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 182
・ TABLE 232 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 183
・ TABLE 233 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 183
・ TABLE 234 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 183
11.4.2 JAPAN 184
11.4.2.1 INCREASING HEALTHCARE EXPENDITURE TO PROPEL MARKET 184
・ TABLE 235 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 184
・ TABLE 236 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 184
・ TABLE 237 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 185
・ TABLE 238 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 185
・ TABLE 239 JAPAN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 185
・ TABLE 240 JAPAN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 186
・ TABLE 241 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 186
・ TABLE 242 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 186
11.4.3 CHINA 187
11.4.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 187
・ TABLE 243 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 187
・ TABLE 244 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 187
・ TABLE 245 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 188
・ TABLE 246 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 188
・ TABLE 247 CHINA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 188
・ TABLE 248 CHINA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 189
・ TABLE 249 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 189
・ TABLE 250 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 189
11.4.4 INDIA 190
11.4.4.1 INCREASING POOL OF START-UPS AND RISING FUNDING INVESTMENTS TO FUEL MARKET 190
・ TABLE 251 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
・ TABLE 252 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 190
・ TABLE 253 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 191
・ TABLE 254 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 191
・ TABLE 255 INDIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 191
・ TABLE 256 INDIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 192
・ TABLE 257 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 192
・ TABLE 258 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 192
11.4.5 SOUTH KOREA 193
11.4.5.1 RISING DEVELOPMENTS BY LEADING MARKET PLAYERS TO BOOST DEMAND 193
・ TABLE 259 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
・ TABLE 260 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 193
・ TABLE 261 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 194
・ TABLE 262 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 194
・ TABLE 263 SOUTH KOREA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 194
・ TABLE 264 SOUTH KOREA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 195
・ TABLE 265 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 195
・ TABLE 266 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 195
11.4.6 AUSTRALIA 196
11.4.6.1 INCREASING ADOPTION OF NOVEL THERAPEUTICS TO SUPPORT MARKET GROWTH 196
・ TABLE 267 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 196
・ TABLE 268 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 196
・ TABLE 269 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 196
・ TABLE 270 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 197
・ TABLE 271 AUSTRALIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 197
・ TABLE 272 AUSTRALIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 197
・ TABLE 273 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 198
・ TABLE 274 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 198
11.4.7 REST OF ASIA PACIFIC 198
・ TABLE 275 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 198
・ TABLE 276 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 199
・ TABLE 277 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 199
・ TABLE 278 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 199
・ TABLE 279 REST OF ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 200
・ TABLE 280 REST OF ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 200
・ TABLE 281 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 200
・ TABLE 282 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 201
11.5 REST OF THE WORLD 201
11.5.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET 201
・ TABLE 283 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 201
・ TABLE 284 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION) 202
・ TABLE 285 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 202
・ TABLE 286 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION) 202
・ TABLE 287 REST OF THE WORLD: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 203
・ TABLE 288 REST OF THE WORLD: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION) 203
・ TABLE 289 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 203
・ TABLE 290 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION) 204
11.5.2 REST OF THE WORLD: RECESSION IMPACT 204

12 COMPETITIVE LANDSCAPE 205
12.1 OVERVIEW 205
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 205
・ FIGURE 39 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS (2021−2024) 205
12.3 REVENUE ANALYSIS 206
・ FIGURE 40 REVENUE ANALYSIS OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, 2022−2032 206
12.4 MARKET SHARE ANALYSIS 206
・ FIGURE 41 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SHARE ANALYSIS (2023) 207
・ TABLE 291 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DEGREE OF COMPETITION 207
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 208
12.5.1 STARS 208
12.5.2 EMERGING LEADERS 208
12.5.3 PERVASIVE PLAYERS 208
12.5.4 PARTICIPANTS 208
・ FIGURE 42 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 209
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 210
12.5.5.1 OVERALL COMPANY FOOTPRINT 210
・ TABLE 292 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: OVERALL COMPANY FOOTPRINT 210
12.5.5.2 REGIONAL FOOTPRINT 210
・ TABLE 293 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: REGIONAL FOOTPRINT 210
12.5.5.3 PRODUCT & SERVICE FOOTPRINT 211
・ TABLE 294 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PRODUCT & SERVICE FOOTPRINT 211
12.5.5.4 TYPE FOOTPRINT 211
・ TABLE 295 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: TYPE FOOTPRINT 211
12.5.5.5 APPLICATION FOOTPRINT 212
・ TABLE 296 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: APPLICATION FOOTPRINT 212
12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES, 2023 212
12.6.1 PROGRESSIVE COMPANIES 212
12.6.2 STARTING BLOCKS 212
12.6.3 DYNAMIC COMPANIES 213
12.6.4 RESPONSIVE COMPANIES 213
・ FIGURE 43 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023 213
12.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023 214
・ TABLE 297 EXOSOME THERAPEUTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 214
12.7 COMPETITIVE SCENARIO 215
12.7.1 DEALS 215
・ TABLE 298 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DEALS, JANUARY 2021−APRIL 2024 215
12.7.2 OTHER DEVELOPMENTS 215
・ TABLE 299 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021−APRIL 2024 215

13 COMPANY PROFILES 216
(BUSINESS OVERVIEW, PRODUCTS/SOLUTIONS/SERVICES OFFERED, RECENT DEVELOPMENTS & MNM VIEW)*
13.1 KEY PLAYERS 216
13.1.1 BIO-TECHNE 216
・ TABLE 300 BIO-TECHNE: COMPANY OVERVIEW 216
・ FIGURE 44 BIO-TECHNE: COMPANY SNAPSHOT (2023) 217
・ TABLE 301 BIO-TECHNE: PRODUCTS/SERVICES OFFERED 218
・ TABLE 302 BIO-TECHNE: DEALS 218
・ TABLE 303 BIO-TECHNE: OTHER DEVELOPMENTS 219
13.1.2 NANOFCM INC. 221
・ TABLE 304 NANOFCM INC.: COMPANY OVERVIEW 221
・ TABLE 305 NANOFCM INC.: PRODUCTS/SERVICES OFFERED 221
13.1.3 SYSTEM BIOSCIENCES, LLC. 222
・ TABLE 306 SYSTEM BIOSCIENCES, LLC.: COMPANY OVERVIEW 222
・ TABLE 307 SYSTEM BIOSCIENCES, LLC.: PRODUCTS/SERVICES OFFERED 223
13.1.4 CAPITAL BIOSCIENCES, INC. 224
・ TABLE 308 CAPITAL BIOSCIENCES, INC.: COMPANY OVERVIEW 224
・ TABLE 309 CAPITAL BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED 224
13.1.5 AMSBIO 225
・ TABLE 310 AMSBIO: COMPANY OVERVIEW 225
・ TABLE 311 AMSBIO: PRODUCTS/SERVICES OFFERED 225
13.1.6 INOVIQ 226
・ TABLE 312 INOVIQ: COMPANY OVERVIEW 226
・ FIGURE 45 INOVIQ: COMPANY SNAPSHOT (2023) 227
・ TABLE 313 INOVIQ: PRODUCTS/SERVICES OFFERED 227
・ TABLE 314 INOVIQ: DEALS 228
13.1.7 DIRECT BIOLOGICS LLC 229
・ TABLE 315 DIRECT BIOLOGICS: COMPANY OVERVIEW 229
・ TABLE 316 DIRECT BIOLOGICS: PRODUCTS/SERVICES OFFERED 229
・ TABLE 317 DIRECT BIOLOGICS: REGULATORY APPROVALS 230
・ TABLE 318 DIRECT BIOLOGICS: OTHER DEVELOPMENTS 230
13.1.8 REGENEUS LTD 231
・ TABLE 319 REGENEUS LTD: COMPANY OVERVIEW 231
・ TABLE 320 REGENEUS LTD: PRODUCTS/SERVICES OFFERED 231
13.1.9 CUREXSYS 232
・ TABLE 321 CUREXSYS: COMPANY OVERVIEW 232
・ TABLE 322 CUREXSYS: PRODUCTS/SERVICES OFFERED 232
13.1.10 AEGLE THERAPEUTICS 233
・ TABLE 323 AEGLE THERAPEUTICS: COMPANY OVERVIEW 233
・ TABLE 324 AEGLE THERAPEUTICS: PRODUCTS/SERVICES OFFERED 233
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS/SOLUTIONS/SERVICES OFFERED, RECENT DEVELOPMENTS & MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
13.2 OTHER PLAYERS 234
13.2.1 MERCY BIOANALYTICS 234
・ TABLE 325 MERCY BIOANALYTICS: COMPANY OVERVIEW 234
13.2.2 NANOSOMIX, INC. 234
・ TABLE 326 NANOSOMIX, INC.: COMPANY OVERVIEW 234
13.2.3 EXONOX BIOSCIENCES, INC. 235
・ TABLE 327 EXONOX BIOSCIENCES, INC.: COMPANY OVERVIEW 235
13.2.4 MULTIMMUNE GMBH 236
・ TABLE 328 MULTIMMUNE GMBH: COMPANY OVERVIEW 236
13.2.5 CAPRICOR THERAPEUTICS, INC. 237
・ TABLE 329 CAPRICOR THERAPEUTICS, INC.: COMPANY OVERVIEW 237
13.2.6 EVOX THERAPEUTICS 238
・ TABLE 330 EVOX THERAPEUTICS: COMPANY OVERVIEW 238
13.2.7 ILIAS BIOLOGICS INC. 239
・ TABLE 331 ILIAS BIOLOGICS, INC.: COMPANY OVERVIEW 239
13.2.8 RION 240
・ TABLE 332 RION: COMPANY OVERVIEW 240
13.2.9 EXOGENUS THERAPEUTICS 241
・ TABLE 333 EXOGENUS THERAPEUTICS: COMPANY OVERVIEW 241
13.2.10 EVERZOM 242
・ TABLE 334 EVERZOM: COMPANY OVERVIEW 242
13.2.11 KIMERA LABS 243
・ TABLE 335 KIMERA LABS: COMPANY OVERVIEW 243

14 APPENDIX

△ 一番上に戻る